Recent Advances on the Development of Pharmacotherapeutic Agents on the Basis of Human Serum Albumin
Recent Advances on the Development of Pharmacotherapeutic Agents on the Basis of Human Serum Albumin
复制标题
DOI：
10.2174/1381612821666150302115411
复制
发表时间：
2015-01-01
影响因子：
3.1
通讯作者：
Xing, Bengang
中科院分区：
文献类型：
--
作者：
Liu, Fang;Mu, Jing;Xing, Bengang
人血清白蛋白（HSA）是血浆中的主要转运蛋白，近年来被报道在药物治疗中发挥着重要作用。由于其具有良好的药物分子内在结合能力，HSA提供了有利的特性，可以直接用作其单体式或可以制成基于蛋白质的纳米颗粒平台，以实现治疗分子有效递送到靶向疾病区域。此外，HSA还可以作为蛋白质稳定剂或环境响应性部分，通过共价反应或静电相互作用与包括聚合物或无机纳米颗粒在内的功能材料杂交，从而极大地改变相关的生物分布和药代动力学行为，以提高其治疗效果。当然，已经进行了广泛的研究来开发HSA缀合的药物，以实现有效的体外和体内疾病诊断和治疗。本文综述了近年来以HSA为载体的蛋白质功能材料的研究进展，主要介绍了HSA载体的偶联类型、剂型及其在药物释放和医学诊断方面的应用前景。
Human serum albumin (HSA), a major transport protein component in blood plasma, has been reported recently to play many important roles in pharmacotherapeutics development. Owing to its promising intrinsic binding capability of drug molecules, HSA offers favorable characteristics and can be directly used as its monomeric formula or can be fabricated into protein based nanoparticle platforms to realize the effective delivery of therapeutic molecules into targeted diseases areas. In addition, HSA can also serve as a protein stabilizer or environment-responsive moieties to hybridize with the functional materials including polymers or inorganic nanoparticles through the covalent reactions or electrostatic interactions, and can thus greatly alter the relevant biological distribution and pharmacokinetic behavior to improve their therapeutic efficacy. By right, extensive studies have been conducted to develop HSA-conjugated pharmacotherapeutic agents toward effective in vitro and in vivo diseases diagnosis and treatment. The current review gives an in-detail account of the latest progresses of HSA-based carriers as functional protein materials, mainly with respect to its conjugation types, formulation aspects, and importantly their promising applications towards enhanced drug delivery and medical diagnosis.